CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DeltaRex-G，一种编码 CCNG1 抑制剂的肿瘤靶向逆转录病毒载体，用于 CAR-T 细胞治疗诱导的细胞因子释放综合征
英文原题：DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.
查看英文原题
DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞因子释放综合征是嵌合抗原受体-T细胞治疗的一种严重并发症，由嵌合T细胞过度分泌炎性细胞因子所触发，可能致命。在探究调控细胞因子释放综合征的分子机制后，我们假设DeltaRex-G——一种编码杀细胞性CCNG1抑制剂基因的肿瘤靶向逆转录载体——可能是治疗皮质类固醇耐药性细胞因子释放综合征的可行选择。DeltaRex-G已获得美国食品药品监督管理局紧急使用授权，用于治疗Covid-19诱导的急性呼吸窘迫综合征，该病由免疫细胞过度活化引起。短暂给予DeltaRex-G将抑制一定比例的高活性嵌合T细胞，从而在保留嵌合T细胞疗效的同时减少细胞因子释放。
展开英文摘要原文
Cytokine release syndrome is a serious complication of chimeric antigen receptor-T cell therapy and is triggered by excessive secretion of inflammatory cytokines by chimeric T cells which could be fatal. Following an inquiry into the molecular mechanisms orchestrating cytokine release syndrome, we hypothesize that DeltaRex-G, a tumor targeted retrovector encoding a cytocidal CCNG1 inhibitor gene, may be a viable treatment option for corticosteroid-resistant cytokine release syndrome.
DeltaRex-G received United States Food and Drug Administration Emergency Use Authorization to treat Covid-19-induced acute respiratory distress syndrome, which is due to hyperactivated immune cells. A brief administration of DeltaRex-G would inhibit a certain proportion of hyperactive chimeric T cells, consequently reducing cytokine release while retaining chimeric T cell efficacy.
论文信息
- 作者
- Haroun G、Gordon EM
- 第一作者单位
- University of California, Los Angeles, Los Angeles, CA, United States.United States
- 通讯作者单位
- Sarcoma Oncology Research Center, Santa Monica CA, Aveni Foundation, Santa Monica, CA, United States.United States
- 期刊
- Frontiers in molecular medicine2024
- 原文标识
- PubMed 39359418 · DOI 10.3389/fmmed.2024.1461151
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →